Introduction
Normal tissue growth, repair and regeneration require ingrowth of blood vessels (angiogenesis) and lymphatics (lymphangiogenesis) to provide proper nutrition and drainage, respectively. However, a similar process governs the uncontrolled growth and spread of various malignancies (Sleeman, 2000; Pepper, 2001) . Indeed, the capacity of tumor cells to induce angiogenesis and lymphangiogenesis may determine the probability of vascular or lymphatic spread of malignancy.
The concept of antiangiogenic therapy was first proposed in the early 1970s as a method of restricting tumor growth (Folkman, 1971) . Many different strategies for antiangiogenesis have been investigated, including those that target endothelial cells (EC) (that is, the anti-vascular endothelial growth factor (VEGF) antibody) (Kim et al., 1993) , mural and stromal cells (Bergers et al., 2003) , hematopoietic cells (Kaplan et al., 2005; Zou, 2005) or neoplastic cells (Izumi et al., 2002) . Furthermore, angiogenesis inhibitors are currently in clinical use worldwide for the treatment of various cancers (Folkman, 2006) .
More recently, several studies have reported an association between VEGF-C expression, tumor lymphangiogenesis and lymph node metastasis in many cancers, including thyroid (Bunone et al., 1999) , prostate (Tsurusaki et al., 1999) , gastric (Yonemura et al., 1999) , colorectal (Akagi et al., 2000) and lung cancers (Niki et al., 2000) . For example, investigators have reported that overexpression of VEGF-C or -D induces lymphangiogenesis and promotes tumor metastasis in mouse tumor models (Karpanen et al., 2001; Mandriota et al., 2001; Skobe et al., 2001; Stacker et al., 2001) , which suggests that lymphatic vessels also regulate tumor metastasis. Indeed, a soluble VEGF receptor (VEGFR)-3-immunoglobulin (Ig) fusion protein has been shown to inhibit VEGF-C-induced tumor lymphangiogenesis (Karpanen et al., 2001) .
In combination, these data suggest that simultaneous targeting of angiogenesis and lymphangiogenesis is an ideal strategy for the treatment of various malignancies in views of antitumor growth and antimetastasis. Therefore, the goal of the present study was to identify novel therapeutic genes that repress both angiogenesis and lymphangiogenesis.
Results
Screening for candidate antiangiogenesis/ antilymphangiogenesis genes A cDNA library obtained from Lewis lung carcinoma (LL/2) was used to screen for candidate genes based on the Folkman's hypothesis applied at discovery of angiostatin and endostatin that cancer cells might produce factors related to not only promoters of angiogenesis and lymphangiogenesis, but also inhibitors of them (Folkman, 2006) . The first screening was performed in canine lymphatic endothelial cells (cLEC) by modified 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTS) assay using the indirect functional screening method with the hemagglutinating virus of Japan envelope (HVJ-E) vector, as previously reported (Nishikawa et al., 2006) . Canine LEC is much superior to human LEC (hLEC) about transfection efficiency and sensitivity of MTS assay (data not shown), as same as relationship of bovine aortic endothelial cells (BAEC) and human AEC (HAEC). This process resulted in identification of 22 candidate antilymphangiogenic genes from the well number 88, which had the lowest value of the cLEC proliferation ( Figure 1a) . Further screening was performed on BAEC by the direct evaluation of c-fos promoter activity after co-transfection with each candidate gene ( Figure 1b ). Gene number 6 had the lowest value in terms of c-fos promoter activity. Gene sequencing revealed that this plasmid DNA sequence matched that encoding the mouse cold shock domain protein A (mCSDA) cDNA (GenBank accession number NM139117.2), which is localized to chromosome 6. Although the reported full open reading frame length of mCSDA was 1086 bp, the plasmid reading frame length was 888 bp because it lacked part of exon 1 (from 67 to 175 bp of the open reading frame). Repeat subcloning of mCSDA from the LL/2 cDNA library by PCR yielded similar results in terms of deletion profiles. Therefore, subsequent experiments utilized this deletion-modified mCSDA sequence.
Expression of mCSDA
Immunofluorescent staining demonstrated that overexpressed mCSDA tagged with hemagglutinin (HA) was localized to the nucleus until at least 48 h after transfection (Figure 2a) . Furthermore, northern blotting demonstrated CSDA mRNA expression in the heart and skeletal muscle of several human tissues, as previously reported (Figure 2b ) (Kudo et al., 1995) . In whole murine embryos, CSDA mRNA was present in low levels until embryonic day 15, and was highly detected at embryonic day 17 (Figure 2b ). Endogenous expression of CSDA was detected in several types of ECs by reverse transcription-PCR (RT-PCR) (Figure 2c ). Interestingly, mCSDA was expressed in aortic and venous ECs and, to a lesser extent, in lymphatic EC, but was barely detected in human aortic smooth muscle cell (HASMC) (Po0.001; Figure 2d ).
Function of mCSDA on LL/2 and ECs Endogenous expression of CSDA was detected in LL/2 by RT-PCR (Figure 3a ). Furthermore, mCSDA mRNA level was upregulated by overexpression of mCSDA plasmid, and was knocked down by RNA interference (RNAi) using small interfering RNA (siRNA). In fact, transfection of siRNA resulted in a 93% decrease in mCSDA mRNA levels, as quantified by real-time RT-PCR. To investigate whether mCSDA has an effect on LL/2 proliferation, mCSDA plasmid or siRNA for mCSDA was transferred into LL/2. Overexpression or repression of mCSDA expression in the cells resulted in no significant change in cellular proliferation, as assessed by MTS assay and c-fos promoter activity after co-transfection with the c-fosluciferase reporter gene ( Figure 3b) .
Next, to confirm the inhibitory effect of mCSDA on EC growth, vascular or lymphatic ECs were co-transfected with the c-fos-luciferase reporter gene and mCSDA plasmid. Overexpression of mCSDA significantly repressed c-fos promoter activity in HAEC, human umbilical vein endothelial cell (HUVEC), hLEC and cLEC, when compared with cells transfected with control plasmid (Po0.001; Figure 3c ). These results demonstrated that mCSDA had inhibitory effect directly on the proliferation of vascular and lymphatic ECs. sequence using a c-fos promoter assay in BAEC or cLEC. Overexpressed mCSDA and hCSDA showed a similar inhibitory effect on c-fos promoter activity in both EC types (Po0.001; Figure 4a ). Since hCSDA could directly bind the promoter region of DNA via exon 1-5, leading to suppression of transcription (Kudo et al., 1995) , the importance of exon 1-5 containing cold shock domain (CSD) in mCSDA was investigated by construction of deletion mutants (DMs). As shown in Figure 4b , three types of DM mCSDA were constructed. DM1 possessed the CSD, whereas DM2 and DM3 lacked the CSD. DM3 also lacked the nuclear localization signal. The c-fos promoter activity was significantly decreased in both of the ECs that overexpressed DM1, but not in ECs that overexpressed DM2 and DM3 without the CSD (Po0.001; Figure 4c ). These results suggest that the CSD plays a key role in the inhibition of EC proliferation.
Mechanisms of mCSDA in ECs
We next focused on the mechanism of EC-proliferated inhibition by mCSDA. Although CSDA inhibits VEGF-A promoter activity by competitive binding with hypoxia inducible factor-1 (HIF-1) to the hypoxia response element (HRE) (Coles et al., 2002) , the key factor of lymphatic EC proliferation is not VEGF-A, but VEGF-C. Furthermore, there is no HIF-1 binding site in the VEGF-C promoter (Chilov et al., 1997) . Thus, the new mechanism of mCSDA was required to explain about repression of both EC types in our results. Since we hypothesized that mCSDA have a potential to widely inhibit effect of growth factors, such as VEGF-A and -C, we compared the cell proliferations with or without the treatment of fetal bovine serum (FBS) as a common paracrine factor on ECs. Indeed, transfection of ECs with mCSDA resulted in a decrease in serum-induced cellular proliferation, as demonstrated by MTS assay (Po0.05; Figure 5a ). Furthermore, cells co-transfected with the c-fos-luciferase reporter gene and mCSDA plasmid showed decreased serum-induced c-fos promoter activity when compared with those transfected with control plasmid (Po0.05; Figure 5b ). The ras/extracellular signal-regulated kinase (ERK) pathway provides a common route of signals from different growth factor receptors, and is a key signaling pathway for the regulation of aortic and lymphatic EC proliferation ( Figure 5c ) Saito et al., 2006) . Consistent with previous reports, ERK was phosphorylated by treatment with recombinant hepatocyte growth factor (HGF) in ECs. However, overexpression of mCSDA did not inhibit the phosphorylation of ERK in BAEC (Figure 5d ). Because mCSDA was reported as a repressor of a number of growth factors , experiments were conducted to determine whether mCSDA could repress the serum response element (SRE), which is the binding site of the last signal of the ERK pathway and also exists in the c-fos promoter.
SRE activity was further evaluated by co-transfection with the SRE-luciferase reporter gene and mCSDA plasmid. Overexpressed CSDA significantly decreased SRE activity compared with that of control plasmid in HAEC, HUVEC, hLEC and cLEC (Po0.05; Figure 6a ). These data suggest that mCSDA could inhibit the SRE activation without inhibition of ERK activation. Similarly, ECs co-transfected with the SRE-luciferase reporter gene and mCSDA plasmid showed decreased seruminduced SRE activity when compared with that of cells transfected with control plasmid (Po0.05; Figure 6b ). Because CSD proteins could repress via direct binding to CT-rich DNA sequence (Shannon et al., 1997) , we hypothesized that mCSDA could directly bind to the SRE sequence to repress the cell growth. Gel mobility shift assay demonstrated that overexpression of the mCSDA gene increased specific binding to the consensus SRE sequence but not to any mutant SRE sequence. Furthermore, preincubation of nuclear extract with anti-CSDA antibody blocked formation of mCSDA-SRE complex. These results indicate that mCSDA could directly bind to the SRE sequence (Figure 6c ).
Antiangiogenesis and antilymphangiogenesis in vivo
Given the in vitro data, we hypothesized that mCSDA would repress tumor angiogenesis and lymphangiogenesis using an LL/2-inoculated mouse model, which was known as a model of the angiogenesis-dependent tumor growth (Supplementary Figure S1a) (Watanabe et al., 2004) , and in Figure 3 , we have already confirmed that mCSDA did not directly influence with LL/2 growth. In an LL/ 2-inoculated mouse model, transfer of mCSDA into the boundary area between tumor and normal tissue was performed using the ultrasound-sonoporation method (Supplementary Figure S1b) (Shimamura et al., 2004) , and tumor size was measured over the subsequent 21 days.
On the flank model at day 21 after LL/2 inoculation, many mature feeding arteries were connected from the host normal tissue to tumor on the green fluorescent protein (GFP)-injected group (control group), but a few weak arteries on mCSDA-injected group (CSDA group) (Figure 7a ). The blood flow by laser Doppler image was significantly lower around the tumor in the CSDA group compared with that in the control group (Po0.01; Figure 7a ). Correspondingly, tumor volume (Po0.01) and weight (Po0.05) was significantly lower in the CSDA group when compared with the control group (Figure 7b) . Furthermore, in this flank model at 21 days after LL/2 inoculation tumor had spread to the Figure 4 Domain analysis of mouse cold shock domain protein A (mCSDA). (a) Effect of mouse mCSDA plasmid, which lacked part of exon 1, and human CSDA (hCSDA) plasmid on c-fos promoter activity in bovine aortic endothelial cells (BAEC) and canine lymphatic endothelial cells (cLEC). GFP plasmid was transfected as control, and hepatocyte growth factor (HGF) plasmid was transfected as a positive control (n ¼ 6, *Po0.001 vs control). (b) Schema of constructs for deletion mutants of mCSDA. mCSDA plasmid lacked a part of exon 1 (red bar). Deletion mutant 1 (DM1); from exon 1 to 9 without part of exon 1 (red line), deletion mutant 2 (DM2); from exon 4 to 9 without CSD, deletion mutant 3 (DM3); from exon 6 to 9 without CSD and the nuclear localization signal (NLS). (c) Comparison of deletion mutants of mCSDA on c-fos promoter activity in BAEC and cLEC. GFP plasmid was transfected as control (n ¼ 6, *Po0.001 vs control, w Po0.001 vs DM 1).
CSDA represses angiogenesis and lymphangiogenesis Y Saito et al lung in the control group, and the number of lung metastasis in the CSDA group was significantly decreased compared with control group (Po0.001; Figures 7c and  d) . The metastasis in lung and inguinal lymph node was also diagnosed by hematoxylin and eosin (H&E) stain (Figure 7e ). We further focused on the histopathological analysis of the boundary area (connecting tissue area) between the main tumor and normal tissue by immunofluorescent staining. Of importance, expression of EC marker, von Willebrand factor (vWF), was low in the normal tissue but high in the tumor tissue in the CSDA group (Figure 8a) . At the boundary area between tumor and normal tissue, the expression of EC markers (vWF and PECAM-1) and capillary density was significantly decreased in CSDA group when compared with the control group (Po0.01; Figures 8b and c) . Furthermore, expression of lymphatic EC marker (Prox1) was only seen in tumor tissue (Figure 9a) , and on the magnification images the expression of lymphatic EC markers (Prox1 and LYVE-1) was decreased in the CSDA groups (Figure 9b) . Indeed, the number of lymphatic vessels was significantly decreased in the CSDA group compared with control group (Po0.05; Figure 9c ).
To further evaluate the metastasis of LL/2 inoculation, we created footpad model, which initially spreads to the inguinal lymph node, using LL/2 stable transfectant expressing luciferase. We also injected the patent blue-staining footpad model was decreased in the CSDA group compared with the control group (frequency, control group: 7/11 (63.6%); CSDA group: 1/7 (14.3%)), and luciferase activity of lymph node was significantly decreased in the CSDA group compared with the control group (Po0.05; Figure 9e ). These data strongly suggested that overexpressed CSDA repressed the growth and metastasis of LL/2 by the antiangiogenic and antilymphangiogenic effect.
Discussion
Inhibition of angiogenesis or lymphangiogenesis is a promising strategy for treatment of cancer, and cancer cells shed from a primary tumor via two major routes, blood and lymphatic vessels, to establish distant metastases. In terms of antiangiogenic or antilymphangiogenic therapy, at least three strategies are feasible: (1) inhibition of the release of angiogenic or lymphangiogenic molecules from tumor cells, that is, inhibition of HIF-1; (2) neutralization of angiogenic or lymphangiogenic molecules that are released from tumors, that is, anti-VEGF antibody (bevacizumab) (Hurwitz et al., 2004) , VEGF165 aptamer (pegaptanib) (Gragoudas et al., 2004) and soluble VEGFR-3-Ig fusion protein (Karpanen et al., 2001) and (3) blockade of the vascular EC response to angiogenic or lymphangiogenic stimulation, that is, endostatin (O'Reilly et al., 1997), tumstatin (Sund et al., 2005) , vasostatin (Pike et al., 1998) and vasohibin (Watanabe et al., 2004) . Although many antiangiogenic or -lymphangiogenic agents have been reported, these agents were limited of the effect because of a great variety of malignancies. We speculate that blockade of one molecule in above three strategies is not enough to fight against cancer cells though antiangiogenesis and antilymphangiogenesis therapy, because some cancer cells may overcome the blockade and rapidly grow. Here, we demonstrate the first report of a multifunctional gene that represses both angiogenesis and lymphangiogenesis, which potentially inhibits VEGF-A promoter activity (Strategy 1) and directly represses vascular and lymphatic EC proliferation via repression of SRE activity (Strategy 3).
Negative regulation is an important physiological mechanism that controls a wide range of phenomena (Lord, 1988) . Folkman (2006) hypothesized that if tumors produce both stimulators and inhibitors of angiogenesis, the stimulators (that is, VEGF) could accumulate in excess of inhibitors within an angiogenic tumor and emergence of tumor angiogenesis was the result of a shift in balance between positive and negative regulators of angiogenesis in a tumor. Thus, the present study screened an LL/2-derived cDNA library to characterize negative regulators of angiogenesis and lymphangiogenesis, as LL/2 cells may form hypervascular tumors and induce metastasis.
Cold shock domain proteins (also called Y-box proteins) repress growth factor and stress response genes via DNA-binding and non-DNA-binding mechanisms (Shannon et al., 1997 . CSDA binds to CT-rich sequences, such as the HRE of the VEGF-A promoter, which subsequently binds to the HIF-1 transcription factor and represses the VEGF-A promoter in normoxic fibroblasts (Coles et al., 2002) . This results in the formation of a CSD protein nuclear complex (Coles et al., 1996; Diamond et al., 2001 ) that may contribute to antiangiogenesis. In contrast, antilymphangiogenesis may require modulation of VEGF-C, as VEGF-C is a common growth factor for lymphatic ECs (VEGF-A is slightly concerned with lymphangiogenesis), and the VEGF-C promoter does not contain an HRE. Thus, the present study focused on the SRE as a target CSDAbinding sequence. As shown in Figure 5c , the ras/ERK pathway provides a common route by which signals from different growth factor receptors converge at a major regulatory element of the promoters of the c-fos and other coregulated genes via the SRE (Hill et al., 1994) . By virtue of its ability to bind to the SRE and compete with Elk-1, CSDA inhibits VEGF-A and VEGFR-2 signaling as well as other signaling pathways mediated by various growth factors, such as VEGF-C, fibroblast growth factor-2 and HGF (Rikitake et al., 2000; Nakagami et al., 2001) . Indeed, inhibition of SRE activation by CSDA represses both angiogenesis and lymphangiogenesis.
In conclusion, the present study demonstrated that gene transfer of CSDA plasmid DNA into ECs repressed both angiogenesis and lymphangiogenesis in vitro and in vivo. These data may help guide the development of novel therapeutics to concomitantly inhibit angiogenesis and lymphangiogenesis in the context of various malignancies.
Materials and methods
Cell culture HAEC, HUVEC and HASMC were maintained as previously described . BAEC, BHK-21 and COS-7 were maintained in Dulbecco's modified Eagle medium containing 10% FBS, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. Human LEC (neonatal dermis) and cLEC that were isolated from canine thoracic ducts as previously described (Saito et al., 2006) were maintained in EBM-2 medium supplemented with 20% FBS and endothelial growth supplement on 0.1% gelatin-coated culture dishes. Cultures were incubated at 37 1C in a humidified atmosphere of 95% air-5% CO 2 with exchange of medium every 2 days. These cells were used at passages 5-8 for subsequent experimental protocols. Cells were transfected using Lipofectamine2000 Transfection Reagent (Invitrogen, Carlsbad, CA, USA).
Establishment of LL/2 stable transfectant expressing luciferase LL/2 cells were plated into six-well plates and transfected with 4 mg per well of pcDNA3.1-luciferase plasmid using Lipofectamine2000 Transfection Reagent (Invitrogen). After 48 h of transfection, the cells were passaged and cultured in medium supplemented with Geneticin (G418) at 400 mg ml À1 for 4 weeks. Stably transfected clones (LL/2/Luc) were picked and maintained in medium containing G418 for additional studies.
cDNA library and functional screening using HVJ-E Functional screening of cDNA library using HVJ-E vector was performed as previously described (Nishikawa et al., 2006) . First, cDNA library was made from LL/2 as previously described (Kobori et al., 1998) , which was amplified once using the Plasmid Giga Kit (Qiagen, Valencia, CA, USA), and infused into HVJ-E vectors as previously described (Kaneda et al., 2002 (Nakagami et al., 2005) , followed by isolation of transfected genes by transformation into Escherichia coli.
Gene transfer protocol for antiangiogenesis and antilymphangiogenesis therapy Male C57BL/6 mice (5-6 weeks old; Oriental Yeast Co. Ltd, Tokyo, Japan) were inoculated intradermally with 5 Â 10 6 LL/ 2 cells. Twenty mice were injected in the right hind flank (flank model) with normal LL/2 cells, and 10 mice were injected in the footpad of there hind leg (footpad model) with LL/2/Luc cells. In total, 30 model mice were randomly assigned to one of two groups: mCSDA plasmid (200 mg per 0.1 ml; inserted on pcDNA3.1) and GFP plasmid (200 mg per 0.1 ml; inserted on pcDNA3.1). Mouse CSDA or GFP plasmid was injected subcutaneously at the boundary area between tumor and normal tissue (Figures 8a and 9a ; inside of white dotted lines) using a 30-gauge needle on days 8, 12, 15 and 19 after inoculation. Injected plasmids were transfected using a microbubble-enhanced ultrasound method, as previously described (Shimamura et al., 2004) .
Tumor size was evaluated periodically, and the tumor volume was calculated as length Â width 2 Â 0.5. Blood flow by laser Doppler imaging (Moor Instruments, Devon, UK) and capillary density within the tumor or around the tumor was assessed for analysis of angiogenesis as previously described . At day 21, 0.2 ml of 0.5% patent blue was injected into the tumor in the footpad model mice for visualization of lymphatic vessels and lymph nodes based on the sentinel node navigation concept. Then all animals were killed and frozen sections were prepared from the excised tissues including the main tumor and connecting normal tissue. Blood or lymphatic vessel quantification was performed by assessing positive immunofluorescent staining for anti-vWF and LYVE-1 in five randomly selected fields as previously described (Yoon et al., 2003) .
All animal protocols were approved by the Animal Ethics Committee of Asahikawa Medical University and by the Osaka University Committee on Animal Research.
Other methods used in this study are described in the Supplementary Methods. 
